North America Enzymatic Wound Debridement Market Size, Share & Trends Analysis Report By End-use, By Type (Chronic Wounds and Acute Wounds), By Product (Collagenase Product, Papain Product, and Others), By Country and Growth Forecast, 2023 - 2030

North America Enzymatic Wound Debridement Market Size, Share & Trends Analysis Report By End-use, By Type (Chronic Wounds and Acute Wounds), By Product (Collagenase Product, Papain Product, and Others), By Country and Growth Forecast, 2023 - 2030


The North America Enzymatic Wound Debridement Market would witness market growth of 5.3% CAGR during the forecast period (2023-2030).

Papain and collagenase-based products treat pressure ulcers, diabetic foot, and venous limb ulcers. The main use of collagenase-based enzymatic wound debridement products is the treatment of surgical wounds. Surgical incisions following cancer surgery are frequently substantial and profound, generating exudate that necessitates constant removal. When treated with the right medicines, large wounds are substantially less susceptible to infection. Consequently, the increasing prevalence of chronic illnesses is expected to stimulate market expansion by bolstering the demand for these products.

Researchers are undertaking various initiatives, and key players are developing technologically advanced products owing to the rising demand for these products regionally, which is anticipated to boost market growth. Since awareness about the use of such products is increasing, several technologically advanced products are being introduced in the market. For instance, NexoBrid (NXB), previously referred to as Debriding Gel Dressing (DGD)—derived from the pineapple Bromelain group of enzymes-was introduced in 2017. NXB is an enzymatic wound-debriding drug that can effectively treat deep burn wounds.

North America has a large and aging population, leading to an increased incidence of wounds associated with age-related conditions. The Centers for Disease Control and Prevention report that the number of obesities in the United States rose from 30.5% to 41.9% between 1999–2000 and 2017–March 2020. Concurrently, the majority of chronic obesity increased from 4.7% to 9.2%. Obesity is a major risk factor for conditions such as diabetes, peripheral vascular disease, and venous lack, which can lead to the development of chronic wounds. Diabetic foot ulcers are more prevalent in individuals with obesity. As the obesity rates grow, so does the occurrence of wounds that require specialized care. As a result, these aspects will boost the market growth in the coming years.

The US market dominated the North America Enzymatic Wound Debridement Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $384.9 million by 2030. The Canada market is experiencing a CAGR of 7.7% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 6.8% during (2023 - 2030).

Based on End-use, the market is segmented into Hospitals, Homecare, and Others. Based on Type, the market is segmented into Chronic Wounds (Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, and Others), and Acute Wounds (Burns, and Others). Based on Product, the market is segmented into Collagenase Product, Papain Product, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ConvaTec Group PLC, Smith & Nephew PLC, Molnlycke Health Care AB, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, Coloplast Group, Medline Industries, Inc., 3M Company, HARTMANN Group (Paul Hartmann AG) and MediWound Ltd

Scope of the Study

Market Segments covered in the Report:

By End-use
  • Hospitals
  • Homecare
  • Others
By Type
  • Chronic Wounds
  • Diabetic Foot Ulcers
  • Pressure Ulcers
  • Venous Leg Ulcers
  • Others
  • Acute Wounds
  • Burns
  • Others
By Product
  • Collagenase Product
  • Papain Product
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America
Companies Profiled
  • ConvaTec Group PLC
  • Smith & Nephew PLC
  • Molnlycke Health Care AB
  • Integra LifeSciences Holdings Corporation
  • B. Braun Melsungen AG
  • Coloplast Group
  • Medline Industries, Inc.
  • 3M Company
  • HARTMANN Group (Paul Hartmann AG)
  • MediWound Ltd
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Enzymatic Wound Debridement Market, by End-use
1.4.2 North America Enzymatic Wound Debridement Market, by Type
1.4.3 North America Enzymatic Wound Debridement Market, by Product
1.4.4 North America Enzymatic Wound Debridement Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. North America Enzymatic Wound Debridement Market by End-use
4.1 North America Hospitals Market by Country
4.2 North America Homecare Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Enzymatic Wound Debridement Market by Type
5.1 North America Chronic Wounds Market by Region
5.2 North America Enzymatic Wound Debridement Market by Chronic Wounds Type
5.2.1 North America Diabetic Foot Ulcers Market by Country
5.2.2 North America Pressure Ulcers Market by Country
5.2.3 North America Venous Leg Ulcers Market by Country
5.2.4 North America Others Market by Country
5.3 North America Acute Wounds Market by Region
5.4 North America Enzymatic Wound Debridement Market by Acute Wounds Type
5.4.1 North America Burns Market by Country
5.4.2 North America Others Market by Country
Chapter 6. North America Enzymatic Wound Debridement Market by Product
6.1 North America Collagenase Product Market by Country
6.2 North America Papain Product Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Enzymatic Wound Debridement Market by Country
7.1 US Enzymatic Wound Debridement Market
7.1.1 US Enzymatic Wound Debridement Market by End-use
7.1.2 US Enzymatic Wound Debridement Market by Type
7.1.2.1 US Enzymatic Wound Debridement Market by Chronic Wounds Type
7.1.2.2 US Enzymatic Wound Debridement Market by Acute Wounds Type
7.1.3 US Enzymatic Wound Debridement Market by Product
7.2 Canada Enzymatic Wound Debridement Market
7.2.1 Canada Enzymatic Wound Debridement Market by End-use
7.2.2 Canada Enzymatic Wound Debridement Market by Type
7.2.2.1 Canada Enzymatic Wound Debridement Market by Chronic Wounds Type
7.2.2.2 Canada Enzymatic Wound Debridement Market by Acute Wounds Type
7.2.3 Canada Enzymatic Wound Debridement Market by Product
7.3 Mexico Enzymatic Wound Debridement Market
7.3.1 Mexico Enzymatic Wound Debridement Market by End-use
7.3.2 Mexico Enzymatic Wound Debridement Market by Type
7.3.2.1 Mexico Enzymatic Wound Debridement Market by Chronic Wounds Type
7.3.2.2 Mexico Enzymatic Wound Debridement Market by Acute Wounds Type
7.3.3 Mexico Enzymatic Wound Debridement Market by Product
7.4 Rest of North America Enzymatic Wound Debridement Market
7.4.1 Rest of North America Enzymatic Wound Debridement Market by End-use
7.4.2 Rest of North America Enzymatic Wound Debridement Market by Type
7.4.2.1 Rest of North America Enzymatic Wound Debridement Market by Chronic Wounds Type
7.4.2.2 Rest of North America Enzymatic Wound Debridement Market by Acute Wounds Type
7.4.3 Rest of North America Enzymatic Wound Debridement Market by Product
Chapter 8. Company Profiles
8.1 ConvaTec Group PLC
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 SWOT Analysis
8.2 Smith & Nephew PLC
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional and Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Molnlycke Health Care AB
8.3.1 Company Overview
8.3.2 SWOT Analysis
8.4 Integra LifeSciences Holdings Corporation
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 B. Braun Melsungen AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 SWOT Analysis
8.6 Coloplast Group
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Medline Industries, LP
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Partnerships, Collaborations, and Agreements:
8.7.2.2 Approvals:
8.7.3 SWOT Analysis
8.8 3M Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 HARTMANN Group (Paul Hartmann AG)
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. MediWound Ltd
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings